Richard Heyman

Dr. Heyman, one of the co-founders, joined the board in September 2014 and has served as the Chairman since June 2015. From August 2013 to April 2015, he served as the Chief Executive Officer of Seragon, which he also co-founded. Prior to joining Seragon, he served as the Chief Executive Officer of Aragon, which he co-founded in 2009. Dr. Heyman has served as Chairman of the Board of Directors of ORIC Pharmaceuticals, Inc., a private company focused on the discovery and development of novel therapies for treatment-resistant cancers, since November 2014. He serves as Vice Chair of the Board of Trustees of The Salk, and is a board member of Gritstone Oncology, Inc., Yumanity Therapeutics Inc., Vividion Therapeutics, Inc., and Mavupharma Inc. Dr. Heyman also serves on the Executive Committee of the Board of Visitors at the UCSD Moores Cancer Center. He received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.